

PTO-1449 REPRODUCED			ATTORNEY DOCKET NO. 2075.1002-003		APPLICATION NO. 09/506,246		
INFORMATION DISCLOSURE CITATION IN AN APPLICATION			APPLICANT Rex T. Gallagher & Garner T. Haupert, Jr.				
September 26, 2000 (Use several sheets if necessary)			FILING DATE February 17, 2000		GROUP 1654 1614		
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
CM	AA	4,780,314	25-OCT-88	Graves, S.W.	424	95	30-OCT-85
CM	AB	5,164,296	17-NOV-92	Blaustein, et al.	435	7.24	
CM	AC	5,429,928	04-JUL-95	Blaustein, et al.	435	7.24	
CM	AD	4,665,019	12-MAY-87	Hamlyn et al.	435	21	
CM	AE	4,551,426	05-NOV-85	Freytag, et al.	435	7	
CM	AF	5,716,937	02-JAN-98	Haupert, Jr., G.T.	514	25	10-FEB-98
CM	AG	4,897,465	30-JAN-90	Cordle, et al.	530	387	
	AH						
	AI						
	AJ						
	AK						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES NO
CM	AL	WO92/04047	19-MAR-92	PCT	—	—	
	AM						
	AN						
	AO						
	AP						
	AQ						
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
CM	AR	Sergio, B. et al., "Effects of an Endogenous Ouabainlike Compound on Heart and Aorta", <i>Hypertension</i> , 17(6): Part 2:944-950 (1991)					
CM	AS	Mathews, W.R. et al., "Mass Spectral Characterization of an Endogenous Digitalis-Like Factor From Human Plasma", <i>Hypertension</i> , 17(6): Part 2:930-935 (1991).					
CM	AT	Ludens, J.H. et al., "Purification of an Endogenous Digitalis-like Factor From Human Plasma for Structural Analysis", <i>Hypertension</i> , 17(6): Part 2: 923-929 (1991).					
EXAMINER			DATE CONSIDERED				
CM			3/21/02				

PTO-1449 REPRODUCED

ATTORNEY DOCKET NO.
2075.1002-003APPLICATION NO.
09/506,246

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION
September 26, 2000
(Use several sheets if necessary)

OIPC
SEP 28 2000
TRADEMARK DESIGN
APPLICANT
Rex T. Gallagher and Garner T. Haupert, Jr.FILING DATE
February 17, 2000GROUP
1654 1614

U.S. PATENT DOCUMENTS

EXAM- INER INI- TIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

CM	AU	Hamlyn, J.M. et al., "Identification and Characterization of a ouabain-like Compound from Human Plasma", Proc. Natl. Acad. Sci. USA, 88:6259-6263 (1991).
	AV	Haber, E. and Haupert, Jr., G.T., "The Search for a Hypothalamic Na, K-ATPase Inhibitors", Hypertension, 9:315-324 (1987).
	AW	Haupert, Jr., G.T., "Overview: Physiological Inhibitors of Na, K-ATPase Concept and Status", The Na ⁺ , K ⁺ -Pump Part B: Cellular Aspects, 297-320 (1988).
	AX	Mudgett-Hunter, M. et al., "High-Affinity Monoclonal Antibodies to the Cardiac Glycoside, Digoxin", J. Immunol., 129(3):1165-1172 (1982).
	AY	Carilli, C.T. et al., "Hypothalamic Factor Inhibits the (Na,K)ATPase from the extracellular Surface", J. Biol. Chem., 260(2):1027-1031 (1985).
	AZ	Janssens, S.P. et al., "Hypothalamic Na ⁺ , K ⁺ -ATPase Inhibitor Constricts Pulmonary Arteries of Spontaneously Hypertensive Rats", J. Cardio. Pharm., 22(Suppl. 2):S42-S46 (1993).
	AR2	Haupert, Jr., G.T. and Sancho, J.M., "Sodium transport inhibitor from bovine hypothalamus", Proc. Natl. Acad. Sci. USA, 76(9):4658-4660 (1979).
	AS2	Haupert, Jr., G.T. et al., "Hypothalamic sodium-transport inhibitor is a high-affinity reversible inhibitor of Na ⁺ -K ⁺ -ATPase", reprint from Am. Physiol. Soc, 247:F919-F924 (1984).
✓	AT2	Mirsalikhova, N.M. et al., "Some Features of the Inhibition of Na ⁺ , K ⁺ -ATPase in Heart Muscle by Cardiotonic Glycosides", Inst. Biochem. and Inst. Chem. Plant Subst., Academy of Sciences of the Urbek SSR, Tashkent, USSR, p. 269-275.

EXAMINER

CM

DATE CONSIDERED

3/21/02

PTO-1449 REPRODUCED			ATTORNEY DOCKET NO. 2075.1002-003		APPLICATION NO. 09/506,246		
INFORMATION DISCLOSURE CITATION IN AN APPLICATION			APPLICANT Rex T. Gallagher and Garner T. Haupert, Jr.				
September 26, 2000 (Use several sheets if necessary)			FILING DATE February 17, 2000		GROUP 1654 1614		
U.S. PATENT DOCUMENTS							
EXAM- INER INI- TIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
<i>CRM</i>	AU2	Pitts, R.F., "Chapter 5, Clearance and Rate of Glomerular Filtration", <i>Physiology of the Kidney and Body Fluids</i> (Year Book Medical Publishers Inc., 3rd Edition, Chicago, IL):60-63.					
	AV2	Mudgett-Hunter, M. et al., "Binding and Structural Diversity Among High-Affinity Monoclonal Anti-Digoxin Antibodies", <i>Mol. Immunol.</i> , 22(4):477-488 (1985).					
	AW2	Smith, T.W. et al., "Treatment of Life-Threatening Digitalis Intoxication with Digoxin-Specific Fab Antibody Fragments", <i>The New England Journal of Medicine</i> , 307(22):1357-1362 (1982).					
	AX2	Smith, T.W. et al., "Reversal of Advanced Digoxin Intoxication with Fab Fragments of Digoxin-Specific Antibodies", <i>The New England Journal of Medicine</i> , 294(15):797-800 (1976).					
	AY2	Hallaq, H.A. and Haupert, Jr., G.T., "Positive inotropic effects of the endogenous Na ⁺ /K ⁺ -transporting ATPase Inhibitor from the hypothalamus", <i>Proc. Natl. Acad. Sci. USA</i> , 86:10080-10084 (1989).					
	AZ2	Axelrod, J., "J. Methylation reactions in the Formation and Metabolism of Catecholamines and Other Biogenic Amines", <i>Pharm. Rev.</i> , 18(1): Part I:95-113 (1966).					
	AR3	Thomas, R. et al., "Synthesis and Biological Activity of Semisynthetic Digitalis Analogs", <i>J. Pharm. Sci.</i> , 63(11):1649-1683 (1974).					
	AS3	Hoffman, B.F. and Bigger, Jr., J.T., "Chapter 34: Digitalis and Allied Cardiac Glycosides", <i>The Pharmacological Basics for Therapeutics</i> , (NY: Pergamon Press):814-839 (1990).					
<i>CRM</i>	AT3	Haupert, Jr., G.T. et al. "Target Organ Sensitivity to an Endogenous Na, K-ATPase Inhibitor from Hypothalamus", <i>Kidney Int.</i> , 31:435A (1987).					
EXAMINER			DATE CONSIDERED <i>CRM</i> 3/21/02				

PTO-1449 REPRODUCED			ATTORNEY DOCKET NO. 2075.1002-003		APPLICATION NO. 09/506,246		
INFORMATION DISCLOSURE CITATION IN AN APPLICATION			APPLICANT Rex T. Gallagher and Garner T. Haupert, Jr.				
September 26, 2000 (Use several sheets if necessary)			FILING DATE February 17, 2000		GROUP 1654 1614		
U.S. PATENT DOCUMENTS							
EXAM- INER INI- TIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
Umm	AU3	Weinberg, U. et al., "Identification and Preliminary Characterization of Two Human Digitalis-Like Substances that are Structurally Related to Digoxin and Ouabain", <i>Biochem. & Biophys. Res. Comm.</i> , 188(3):1024-1029 (1992).					
	AV3	Tamura, M. et al., "Isolation and Characterization of a Specific Endogenous Na ⁺ , K ⁺ -ATPase Inhibitor from Bovine Adrenal", <i>Biochem.</i> , 27:4244-4253 (1988).					
	AW3	Schoner, W. et al., "Purification and Properties of Endogenous Ouabain-like Substances from Hemofiltrate and Adrenal Glands", <i>J. Cardiovas. Pharm.</i> , 22(Suppl. 2):S29-S31 (1993).					
	AX3	Lewis, L.K. et al., "Ouabain Is Not Detectable in Human Plasma", <i>Hypertension</i> , 24(5):549-555 (1994).					
	AY3	Valdes, Jr., R. & Graves S.W. "Protein Binding of Endogenous Digoxin-Immunoactive Factors in Human Serum and Its Variation with Clinical Condition", <i>J. Clin. Endoc. Metab.</i> , 60(6):1135-1143 (1985).					
	AZ3	Illescas, M. et al., "Complete purification of two identical Na ⁺ -pump inhibitors isolated from bovine hypothalamus and hypophysis", <i>FEBS Let.</i> , 261(2):436-440 (1990).					
	AR4	Zhao, N. et al., "Na,K-ATPase Inhibitors from Bovine Hypothalamus and Human Plasma Are Different from Ouabain: Nanogram Scale CD Structural Analysis", <i>Biochem.</i> , 34:9893-9896 (1995).					
	AS4	Tymiak et al., "Physicochemical Characterization of a Ouabain Isomer Isolated from Bovine Hypothalamus", <i>Proc. Natl. Acad. Sci.</i> , 90:8189-8193 (1993).					
✓	AT4	Nakanishi et al., "Search for an Endogenous Mammalian Cardiotonic Factor", <i>Saponins Used in Traditional and Modern Medicine</i> , pp:219-224 (1996).					
EXAMINER Cmm			DATE CONSIDERED 3/21/02				

PTO-1449 REPRODUCED INFORMATION DISCLOSURE CITATION IN AN APPLICATION September 26, 2000 (Use several sheets if necessary)			ATTORNEY DOCKET NO. 2075.1002-003	APPLICATION NO. 09/506,246			
			APPLICANT Rex T. Gallagher and Garner T. Haupert, Jr.				
			FILING DATE February 17, 2000	GROUP 1654 1614			
U.S. PATENT DOCUMENTS							
EXAM- INER INI- TIAL		DOCUMENT NUMBER	DATE 	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
CM	AU4	Anner et al., "Hypothalamic Na ⁺ -K ⁺ -ATPase Inhibitor Characterized in Two-Sided Liposomes Containing Pure Renal Na ⁺ -K ⁺ -ATPase", Am. J. Physiol., 258 (Renal Fluid Electrolyte Physiol., 27):F144-F153 (1990).					
	AV4	Berzoksky, J.A. and Berkower, I.J., "Immunogenicity and Antigen Structure," In Fundamental Immunology, Paul, W.E., ed., (NY:Raven Press), p. 242 (1993).					
CM	AW4	Montali, U., et al., "Purification of Endogenous Digitalis-Like Factor(s) from Cord Blood of Neonate by Immunoaffinity Chromatography," Biochem. Int;25:853-859 (1991) ✓					
EXAMINER CM			DATE CONSIDERED 3/21/02				